We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$5.44B
AUM Growth
+$635M
Cap. Flow
+$416M
Cap. Flow %
7.65%
Top 10 Hldgs %
15.63%
Holding
579
New
166
Increased
105
Reduced
70
Closed
180

Sector Composition

Rank Sector Weight
1 Real Estate 17.07%
2 Consumer Staples 11.62%
3 Industrials 7.66%
4 Financials 6.61%
5 Consumer Discretionary 6.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KBIO
526
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
-15,625
Closed -$565K
HR
527
DELISTED
Healthcare Realty Trust Incorporated
HR
-92,912
Closed -$2.15M

Similar funds

UBS O'Connor's Q4 2013 Portfolio in Review

As of Q4 2013, UBS O'Connor held 579 positions worth $5.44B, up 13% from $4.81B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

UBS O'Connor deployed $416M of net new capital in Q4 2013, opening 166 new positions and adding to 105 existing holdings. Its largest new stake was American Airlines Group: 2,596,600 shares worth $65.6M.

By sector, the portfolio is most concentrated in Real Estate at 17% of assets, up from 15% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was Colgate-Palmolive, an estimated $46.1M trimmed.

  • UBS O'Connor's largest Q4 2013 buy was American Airlines Group: 2,596,600 shares worth $65.6M.
  • UBS O'Connor added most to Crown Castle in Q4 2013, an estimated $53.8M increase.
  • UBS O'Connor's biggest Q4 2013 reduction was Colgate-Palmolive, cutting an estimated $46.1M.
  • UBS O'Connor fully exited ONYX PHARMACEUTICALS INC in Q4 2013, selling an estimated $60.5M.
  • UBS O'Connor's ten largest holdings make up 16% of its $5.44B portfolio in Q4 2013.
  • UBS O'Connor opened 166 new positions and closed 180 in Q4 2013.
  • UBS O'Connor's portfolio value rose 13% quarter-over-quarter to $5.44B.

Based on UBS O'Connor's 13F filing for Q4 2013, filed 13 Feb 2014.